We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Mapping the Tumor Microenvironment in Multiple Myeloma: Insights from Single-Cell Analysis Across Disease Stages

MedXY Editorial Team•Oct 16, 2026•Hematology-Oncology
bone marrowimmunotherapymultiple myelomasingle-cell RNA sequencingTumor Microenvironment

Highlight

  • Single-cell RNA and T-/B-cell receptor sequencing of 235 bone marrow samples reveals dynamic immune landscape changes across multiple myeloma progression.
  • Identification of five distinct tumor microenvironment (TME) ecotypes characterized by unique immune cell compositions and functional states independent of disease stage.
  • Specific ecotypes correlate with clinical outcomes, tumor burden, and immunotherapy response, highlighting potential for ecotype-driven, stage-specific immunotherapies.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic StrategyThis review synthesizes evidence on disitamab vedotin combined with tislelizumab showing promising efficacy and safety in treating transurethrally unresectable ERBB2-positive very high-risk NMIBC, filling a crucial therapeutic gap for patieOct 15, 2026High Efficacy and Safety of Glofitamab Plus Polatuzumab-R-CHP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Multicenter StudyA phase II trial shows that adding the bispecific antibody glofitamab to polatuzumab-R-CHP achieves a 95% complete response rate and durable remission with minimal cytokine release syndrome in high-risk diffuse large B-cell lymphoma.Oct 11, 2026Targeting the FGF18-FGFR3 Axis: A New Frontier in Acute Myeloid Leukemia TherapyFGF18 produced by stromal fibroblasts promotes AML progression via FGFR3-mediated AKT-mTOR signaling, forming a feed-forward loop that impairs CD8+ T-cell immunity. Neutralizing FGF18 synergizes with PD-1 blockade, suggesting a novel therapOct 9, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Decoding CTCL: A Single-Cell Atlas Reveals Oncogenic Pathways and Immune Resistance Mechanisms
This study presents a comprehensive single-cell RNA-sequencing atlas of CTCL, identifying oncogenic transcriptional programs and immune microenvironment features that offer new therapeutic targets for advanced-stage disease.
Oct 8, 2026
Immunotherapy-Induced Endocrine Dysfunction in Gynecologic Oncology: Clinical Insights from a Retrospective Cohort StudyThis study highlights the prevalence, clinical features, and management challenges of immune-related thyroid and diabetes toxicities in gynecologic cancer patients treated with immunotherapy, emphasizing the need for proactive endocrine monOct 4, 2026
Precision Medicine in Type 1 Diabetes Prevention: Long-Term Delayed Onset of Stage 3 Diabetes After GAD-Alum Treatment in HLA-DR3-DQ2-Positive ChildrenGAD-alum immunotherapy significantly delays progression to stage 3 type 1 diabetes in children positive for the HLA-DR3-DQ2 haplotype, underscoring precision medicine’s role in managing autoimmunity.Oct 4, 2026